Find Out What
Can Mean for Your Patients1-3
Mozobil + granulocyte-colony stimulating factor (G-CSF) has been shown to improve mobilization compared to G-CSF alone in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).Get the Details
Mozobil is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with NHL and MM.1
Mozobil is a first in class CXCR4 receptor antagonist.1
Begin treatment with Mozobil after the patient has received G-CSF once daily for 4 days. Administer Mozobil approximately 11 hours before initiation of each apheresis while continuing daily G-CSF administration. Mozobil administration can be up to 4 consecutive days.1
The Sanofi Patient Connection (SPC) provider portal allows you to enroll and manage your patients in the suite of access services. The secure web-based portal is available 24 hours a day, 7 days a week.